These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10584928)

  • 1. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector.
    Harvey BG; Worgall S; Ely S; Leopold PL; Crystal RG
    Hum Gene Ther; 1999 Nov; 10(17):2823-37. PubMed ID: 10584928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals.
    Harvey BG; Hackett NR; Ely S; Crystal RG
    Mol Ther; 2001 Feb; 3(2):206-15. PubMed ID: 11237677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
    Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
    J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
    Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
    Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
    Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
    Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
    Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
    Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene.
    van Ginkel FW; McGhee JR; Liu C; Simecka JW; Yamamoto M; Frizzell RA; Sorscher EJ; Kiyono H; Pascual DW
    J Immunol; 1997 Jul; 159(2):685-93. PubMed ID: 9218583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
    Crystal RG; Harvey BG; Wisnivesky JP; O'Donoghue KA; Chu KW; Maroni J; Muscat JC; Pippo AL; Wright CE; Kaner RJ; Leopold PL; Kessler PD; Rasmussen HS; Rosengart TK; Hollmann C
    Hum Gene Ther; 2002 Jan; 13(1):65-100. PubMed ID: 11779413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.
    Alzuguren P; Hervas-Stubbs S; Gonzalez-Aseguinolaza G; Poutou J; Fortes P; Mancheno U; Bunuales M; Olagüe C; Razquin N; Van Rooijen N; Enguita M; Hernandez-Alcoceba R
    Liver Int; 2015 Apr; 35(4):1274-89. PubMed ID: 24754307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression.
    Harrod KS; Hermiston TW; Trapnell BC; Wold WS; Whitsett JA
    Hum Gene Ther; 1998 Sep; 9(13):1885-98. PubMed ID: 9741427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
    Kuzmin AI; Galenko O; Eisensmith RC
    Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
    Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
    Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
    Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
    Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene.
    Korst RJ; Ailawadi M; Lee JM; Lee S; Yamada R; Mahtabifard A; Crystal RG
    Hum Gene Ther; 2001 Sep; 12(13):1639-49. PubMed ID: 11535167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade.
    Jiang Z; Schiedner G; van Rooijen N; Liu CC; Kochanek S; Clemens PR
    Mol Ther; 2004 Oct; 10(4):688-96. PubMed ID: 15451453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
    Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
    Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
    Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
    Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency.
    Petrof BJ; Lochmüller H; Massie B; Yang L; Macmillan C; Zhao JE; Nalbantoglu J; Karpati G
    Hum Gene Ther; 1996 Oct; 7(15):1813-26. PubMed ID: 8894673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.